Explore

Innovations

Healthcare & Pharmaceuticals

Treatment for Multiple Myeloma

This technology is a SR-18465 compound, which is an osteoclastogenesis matrix metalloproteinase 13 (MMP-13) highly specific inhibitor for the treatment of multiple myeloma.

By Florida Atlantic University

Do you have an innovative technology, product or service?

Add your solution to the world’s most advanced open innovation platform and get seen by global corporations seeking new solutions – all free of charge.

View all

Keep your eye on the ball, subscribe to our email marketing to stay up to date with LEO.